From the Journals

SCD: Delaying Transition to Adult Care Poses Risks


 

TOPLINE:

A recent study suggests that delays in transitioning from pediatric to adult health care can increase hospitalizations and emergency department visits for young adults with sickle cell disease (SCD).

METHODOLOGY:

  • Guidelines have recommended that young adults with SCD transfer from pediatric care within 6 months, but many transfers take longer — sometimes up to a year.
  • Researchers evaluated the impact of prolonged transition gaps on health outcomes in 183 young adults who completed pediatric care between 2012 and 2018 and were transitioned to an adult care program. Patients were followed for 2-8 years from their first adult care visit.

TAKEAWAY:

  • Approximately 88% of patients transferred to adult health care within 6 months, with a median transfer gap of 1.4 months. At 2 years of adult care, patients with a transition gap of 6 months or longer were 89% (relative risk, 1.89) more likely to have an inpatient visit and 75% (RR, 1.75) more likely to have ED visits.
  • Those with transfer gaps of 6 months or longer had twice the rate of inpatient visits (rate ratio, 2.01) at 8 years of follow-up, compared with those who transitioned within 2 months.
  • However, fewer adult care outpatient visits were seen (5.1 vs 6.7 visits per year) for young adults transferred in 6 or more months versus those within 6 months.

IN PRACTICE:

According to the authors, “longer delays in establishing adult health care following pediatric care were associated with greater acute health care resource utilization and fewer health care maintenance (ie, outpatient) SCD visits. These findings emphasize the importance of swift transfer from pediatric to adult care among young adults with SCD.”

SOURCE:

The study was led by Kristen E. Howell, of the Department of Epidemiology and Biostatistics, Texas A&M School of Public Health, College Station, Texas, and was published online in Blood Advances.

LIMITATIONS:

Data was available only for patients within a specific health care system, limiting the generalizability of the findings. Involving only one pediatric and two adult programs could impact findings. Insurance loss or changes due to low income were not accounted for.

DISCLOSURES:

The study was funded by U1EMC19331 and the American Lebanese Syrian Associated Charities. The authors declared no relevant conflicts of interest.

Recommended Reading

FDA approves first 2 gene-editing therapies for sickle cell
MDedge Hematology and Oncology
Sickle Cell Gene Therapy ‘Truly Transformative’
MDedge Hematology and Oncology
Sickle Cell: Good Outcomes for Haploidentical Transplants
MDedge Hematology and Oncology
SCD mortality rates improved for Black patients in 2010s
MDedge Hematology and Oncology
Sickle Cell CRISPR Gene Therapy May Offer Patients ‘Functional Cure’
MDedge Hematology and Oncology
CRISPR-Based Gene Therapy Earns Beta Thalassemia Approval
MDedge Hematology and Oncology
Democratic Lawmakers Press Pfizer on Chemotherapy Drug Shortages
MDedge Hematology and Oncology
EU Backs First Oral Monotherapy for Adults With PNH
MDedge Hematology and Oncology
FDA OKs Danicopan Add-On for Extravascular Hemolysis in Adults With PNH
MDedge Hematology and Oncology
FDA Approves Second Gene Therapy for Hemophilia B
MDedge Hematology and Oncology